Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $53.67 Consensus Target Price from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has earned a consensus rating of “Reduce” from the ten ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and nine have issued a hold rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $29.15.

CAPR has been the topic of several research reports. LADENBURG THALM/SH SH lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a report on Monday. Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Oppenheimer restated a “market perform” rating on shares of Capricor Therapeutics in a research note on Monday. Finally, Cantor Fitzgerald lowered Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.50 price target on the stock. in a research report on Thursday.

Capricor Therapeutics Trading Down 36.2%

Shares of NASDAQ:CAPR opened at $4.19 on Friday. The firm has a 50 day simple moving average of $23.50 and a 200-day simple moving average of $26.93. Capricor Therapeutics has a twelve month low of $2.96 and a twelve month high of $40.37. The company has a market capitalization of $242.64 million, a PE ratio of -1.81 and a beta of 0.42.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts predict that Capricor Therapeutics will post -0.84 EPS for the current fiscal year.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Supportive clinical data: The Lancet published HOPE-3 Phase 3 results, reporting that deramiocel met the study’s primary endpoint and slowed upper-limb function decline by 54% versus placebo, while also showing potential cardiac benefits. The Lancet Publishes HOPE-3 Data
• Neutral Sentiment: The FDA vote is non-binding: Capricor said the advisory committee voted 3-9 that available evidence did not support deramiocel’s effectiveness for DMD cardiomyopathy. The FDA is not required to follow the panel’s recommendation, but the vote signals a substantial regulatory hurdle ahead of the agency’s final decision. Capricor FDA Advisory Committee Update
• Negative Sentiment: FDA questioned the company’s efficacy claims: FDA briefing materials reportedly concluded that deramiocel failed to demonstrate statistically significant benefits on its prespecified cardiac endpoint, creating a data dispute with Capricor’s interpretation of the HOPE-3 results. Capricor Duchenne Cell Therapy Voted Down
• Negative Sentiment: Analysts cut ratings and targets: Oppenheimer, Maxim Group, Cantor Fitzgerald, Ladenburg Thalmann and Alliance Global Partners downgraded the stock following the vote. Cantor assigned a $3.50 target, implying additional downside from the cited share price. Capricor Downgraded at Oppenheimer
• Negative Sentiment: Investor investigations add pressure: Multiple law firms announced investigations into possible securities-law violations and alleged misleading statements regarding deramiocel’s trial results. These announcements do not establish wrongdoing, but they increase legal and reputational risk. Capricor Plummets After FDA Panel Vote

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 25,000 shares of company stock worth $759,158 in the last 90 days. Company insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its holdings in shares of Capricor Therapeutics by 12.4% in the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 557 shares during the last quarter. KBC Group NV purchased a new position in shares of Capricor Therapeutics during the first quarter worth about $44,000. ACT Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at about $43,000. Nuveen LLC increased its position in Capricor Therapeutics by 2.1% in the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock valued at $2,625,000 after acquiring an additional 1,878 shares during the period. Finally, State of Wyoming raised its stake in Capricor Therapeutics by 76.0% during the 4th quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after acquiring an additional 1,913 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.